Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics
The new gene editing joint venture being formed by Bayer and CRISPR Therapeutics is taking shape. Now dubbed Casebia Therapeutics, the fledgling operations has begun hiring dozens of new staffers, taking up a temporary residence while its new home is being built in Kendall Square in Cambridge, MA.
The upstart biotech effort just inked a lease on 33,000 square feet of space at 610 Main Street North, a nine-story building currently under construction near Kendall Square and adjacent to the MIT campus. This is the second MIT-owned building here, with Pfizer R&D occupying the first. The company will be co-located with CRISPR Therapeutics’ R&D ops in the center of a thriving biotech cluster that will be home for up to 80 staffers, while another group will be located in Bayer’s Mission Bay campus in San Francisco.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.